We are delighted to announce that Pearce IP’s founder and CEO Naomi Pearce has been honoured by Australasian Lawyers as one of Australia’s Most Influential Lawyers in 2023....
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
We are delighted to announce that Pearce IP is ranked in the Chambers and Partners Guide for 2024 in the category of Intellectual Property. Pearce IP’s Founder and CEO Naomi...
15 DEC 2023 | KR | Approval Alert: LG Chem’s Xelenka® Biosimilar to AbbVie’s Humira® (adalimumab) Approved in Korea Korea Biomed reported that LG Chem’s Xelenka®, biosimilar to...
08 DEC 2023 | US | FDA Approves First Cell-Based Gene Therapies Casgevy® and Lyfgenia® to Treat Sickle Cell Disease The FDA approved Vertex/CRISPR Therapeutics’ Casgevy® and...
Pearce IP is proud to announce that Jacinta Flattery-O’Brien PhD has again been named as one of Australia’s patent elite in the 2024 edition of IAM Global Leaders. Jacinta is...
01 DEC 2023 | US | Celltrion Files BLA for Interchangeable Prolia® (Denosumab) Biosimilar with the FDA The Korea Biomedical Review reported that Celltrion has submitted an...
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
24 NOV 2023 | Celltrion Applies For EU Approval of CT-P42, Biosimilar to Regeneron’s Eylea® (aflibercept) Celltrion revealed in a corporate filing with the Repository of Korea’s...
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
16 NOV 2023 | US | Approval Alert: AZ’s Truqap® (capivasertib) plus Faslodex® FDA Approved to Treat Advanced HR-positive Breast Cancer AstraZeneca (AZ) announced the FDA...
On 9 August 2023, the Registrar of Trade Marks handed down a decision in favour of Nova Pharmaceuticals Australasia Pty Ltd (Nova) regarding its GLUCO BOOST trade mark in an...
Managing IP (MIP) has honoured Pearce IP as the only known ANZ IP firm founded by a woman. Separately, WEConnect International has certified Pearce IP as Women Owned. CEO and...
10 NOV 2023 | EU | CHMP Positive Opinion for 8mg Eylea® (Aflibercept) Bayer announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended...
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
With over 150 rivaroxaban products approved (9 of them for Bayer), the outcome of the Sandoz challenge to the validity of the AU Bayer (Xarelto®) patents may be the case with the...
01 NOV 2023 | EU | Fresenius Kabi’s Launches First EU Tocilizumab Biosimilar Fresenius Kabi announced it has launched Tyenne®, the first EC-approved biosimilar to Roche’s...
The Australian government has made numerous claims for damages against patentees for savings forgone when an interlocutory/preliminary injunction (PI) delays generic launch but...
27 OCT 2023 | US | Sanofi to Spin-Off Consumer Business and Focus on Biopharma by End Q4 2023 Sanofi announced that it will separate its Consumer Healthcare Business as soon as...
Pearce IP is delighted to announce that leading intellectual property specialist Julie Ballance (Patent Attorney, Lawyer and Notary, NZ) commenced with Pearce IP as a Special...
23 OCT 2023 | US | Approval Alert: FDA Approves Celltrion’s Zymfentra® (infliximab-dyyb), Biosimilar to Janssen’s Remicade®, and the First Approved SC Infliximab...
15 OCT 2023 | Samsung Bioepis Reveals SB16 (denosumab) Study Results at ASBMR Samsung Bioepis presented new data on its SB16 (denosumab, biosimilar to Amgen’s Prolia®) at the...
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
An Australian Court has found in favour of Globaltech which solved a mining problem with an elegant solution. An important lesson from this decision is that driving IP innovation can be central to maintaining a market-leading position.
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.
